Allegro has devised a molecular testing platform that makes use of a genomic biomarker to detect early signs of lung cancer in current and former smokers.
BronchoGen genomic test is used in combination with standard bronchoscopy for the early diagnosis of lung cancer.
Allegro Diagnostics president and CEO Mike Webb said the licensing agreement with Boston University and theUniversity of Utah Foundation helps them to achieve that goal by supporting their advancement of this platform,including the planned commercial launch of BronchoGen in the first half of 2012.